What is Ablacon?
Founded in 2015 and headquartered in Wheat Ridge, Colorado, Ablacon is a specialized MedTech firm focused on the intersection of artificial intelligence and electrophysiology. The company's core innovation lies in its ability to analyze and visualize Electrographic Flow within the heart, providing clinicians with actionable insights to identify the specific sources of AFib. This diagnostic precision is intended to improve the efficacy of ablation procedures, thereby reducing recurrence rates and enhancing patient outcomes in a market segment that remains a significant challenge for global healthcare systems.
How much funding has Ablacon raised?
Ablacon has raised a total of $63.5M across 4 funding rounds:
Multiple Rounds
$33.5M
Series B
$30M
Series A (2019): $21.5M with participation from Ajax Health
Debt (2019): $10M led by Western Technology Investment
Private Equity (2019): $2M supported by Western Technology Investment
Series B (2021): $30M featuring Zeus Health Products Ltd
Key Investors in Ablacon
Ajax Health
Ajax Health is a strategic investment firm that focuses on building and scaling innovative medical technology companies through deep operational expertise and capital support.
Western Technology Investment
Western Technology Investment (WTI) specializes in providing venture debt to assist startups in financing their growth while minimizing shareholder dilution. Since its inception in 1980, WTI has supported over 1,400 companies across various innovation sectors, demonstrating a long history of capital provision through diverse economic cycles.
Zeus Health Products Ltd
Zeus Health Products Ltd is a strategic investor focused on the healthcare sector, providing capital to support the advancement of medical technologies and clinical solutions.
What's next for Ablacon?
With the recent completion of its Series B round, Ablacon is well-positioned to scale its operations and expand the clinical adoption of its AFib mapping technology. The strategic deployment of this capital will likely focus on accelerating regulatory milestones, broadening the reach of its AI-driven diagnostic suite, and strengthening its intellectual property portfolio. As the company transitions from a development-focused entity to a commercial-stage leader, the focus will shift toward establishing long-term clinical evidence and securing broader market penetration within the global electrophysiology sector. The continued support from both venture debt providers and strategic health investors provides the necessary financial runway to navigate the complexities of the medical device regulatory environment while maintaining a competitive edge in heart rhythm management.
See full Ablacon company page
